Yu-Waye Chu - Jan 25, 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Medical Officer
Signature
/s/ Cindy Tahl, Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Jan 25, 2022
Transactions value $
$0
Form type
4
Date filed
1/27/2022, 03:37 PM
Previous filing
Jan 13, 2022
Next filing
Apr 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Award $0 +33.3K +27.34% $0.00 155K Jan 25, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Award $0 +53.1K $0.00 53.1K Jan 25, 2022 Common Stock 53.1K $39.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date.
F2 The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date.